» Articles » PMID: 10489039

Dysregulation of the Hypothalamo-pituitary-adrenal Axis is Related to the Clinical Course of MS

Overview
Journal Neurology
Specialty Neurology
Date 1999 Sep 17
PMID 10489039
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate whether dysregulation of the hypothalamo-pituitary-adrenal (HPA) axis is related to clinical characteristics in MS.

Methods: The authors performed the combined dexamethasone-corticotropin-releasing hormone test (Dex-CRH test) in 60 MS patients and 29 healthy control subjects. In addition, the short adrenocorticotropic hormone (ACTH) test was performed in 39 consecutive patients. All patients had active disease and none were treated with glucocorticoids, immunosuppressants, or immunomodulators.

Results: The patients had an exaggerated rise in plasma cortisol concentrations in the Dex-CRH test (p < 0.05), indicating hyperactivity of the HPA system. The degree of hyperactivity was moderate in relapsing-remitting MS patients (n = 38; area under the time-course curve for cortisol [AUC-Cort] 226.2+/-38.9 arbitrary units [AU], mean +/- SEM), intermediate in secondary progressive MS patients (n = 16; AUC-Cort, 286.8+/-60.2 AU), and marked in primary progressive MS patients (n = 6; AUC-Cort, 670.6+/-148.6 AU). Differences were significant between the three patient groups (p < 0.005), and between control subjects (n = 29; AUC-Cort, 150.8+/-34.1 AU) and each patient group. Indicators of HPA axis activation correlated with neurologic disability (Kurtzke's Expanded Disability Status Scale), but not with the duration of the disease, number of previous relapses, previous corticosteroid treatments, or depressed mood (Hamilton Depression Scale). The ACTH test was normal in 31 of the 33 patients studied.

Conclusion: HPA axis hyperactivity in MS is related to the clinical type of disease, with a suggestion of increasing HPA axis dysregulation with disease progression.

Citing Articles

Alterations in the Hypothalamic-Pituitary-Adrenal Axis as a Response to Experimental Autoimmune Encephalomyelitis in Rats of Both Sexes.

Milosevic A, Milosevic K, Zivkovic A, Lavrnja I, Savic D, Bjelobaba I Biomolecules. 2024; 14(8).

PMID: 39199407 PMC: 11352252. DOI: 10.3390/biom14081020.


Effects of Psychological Stress on Multiple Sclerosis HPA Axis-mediated Modulation of Natural Killer T Cell Activity.

Gao Y, Liu W, Liu P, Li M, Ni B CNS Neurol Disord Drug Targets. 2024; 23(12):1450-1462.

PMID: 38818912 DOI: 10.2174/0118715273315953240528075542.


Impact of endocrine dysregulation on disability and non-motor symptoms in pediatric onset multiple sclerosis.

Abe J, Jafarpour S, Vu M, OBrien D, Boyd N, Vogel B Front Neurol. 2023; 14:1304610.

PMID: 38130835 PMC: 10733457. DOI: 10.3389/fneur.2023.1304610.


Association of rare variants in genes of immune regulation with pediatric autoimmune CNS diseases.

Jafarpour S, Banerjee A, Boyd N, Vogel B, Paulsen K, Ahsan N J Neurol. 2022; 269(12):6512-6529.

PMID: 35960392 PMC: 9372976. DOI: 10.1007/s00415-022-11325-2.


Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response.

Evangelopoulos M, Nasiri-Ansari N, Kassi E, Papadopoulou A, Evangelopoulos D, Moutsatsou P Sci Rep. 2021; 11(1):19462.

PMID: 34593869 PMC: 8484573. DOI: 10.1038/s41598-021-98868-y.